Oncolytic viruses (OVs) are a class of viruses that selectively infect and replicate in tumor cells. Their anti-tumor activity is driven by two complementary mechanisms: direct oncolysis—virus-mediated tumor cell lysis and subsequent spread to adjacent cancer cells—and immune activation—release of tumor-associated antigens and immunostimulatory factors (e.g., GM-CSF, interferons) that reshape the tumor microenvironment and trigger systemic anti-tumor immunity.
To enhance safety, tumor specificity, and therapeutic efficacy, oncolytic viruses are often engineered through targeted genetic modifications—such as gene deletions, insertions, or substitutions—to enable selective replication in cancer cells while minimizing damage to healthy tissues.
Fig.1 Strategies for Oncolytic Virotherapy PMID: 34638863
At BrainVTA, we offer a comprehensive technology platform for oncolytic virus development, supporting engineering, production, and functional evaluation across multiple virus backbones, including: Herpes simplex virus (HSV), Adenovirus (AdV), Vaccinia virus (VACV), Vesicular stomatitis virus (VSV), Reovirus (ReV).
From discovery to commercialization, our integrated platform accelerates the development of next-generation oncolytic virus therapeutics.
Workflow
Our end-to-end services span customized engineering, process development, and pharmacology evaluation, ensuring seamless transition from research to GMP-ready manufacturing.
Engineering Services by Virus Type
Herpes Simplex Virus (HSV)
HSV is widely used in oncolytic virus research due to its broad host tropism, rapid replication cycle, and large cargo capacity (up to 30 kb). BrainVTA provides well-characterized HSV-1 strains (HSV-F, HSV-KOS, HSV-129) and multiple engineering strategies. For more information, contact us at
[email protected].
|
Catalog No. |
Product |
Strain |
Reporter |
Description |
|
H05001 |
HSV Wild Type |
HSV-1 (KOS) |
— |
— |
|
H06001 |
HSV Wild Type |
HSV-1 (F) |
— |
— |
|
H06002 |
HSV-△ICP34.5 |
HSV-1 (F) |
EGFP |
Safety modification: ICP34.5 deletion |
Adenovirus (AdV)
Adenovirus offer high transduction efficiency, broad host range, non-integrating genome (favorable safety profile), and a cargo capacity of approximately 8 kb.
BrainVTA offers AdV serotype 5 (Ad5)-based platforms with multiple engineering strategies.
|
Catalog No. |
Product |
Strain |
Reporter |
|
AD-18 |
AD-EGFP (Replication-competent) |
Ad5 |
EGFP |
|
OVAD-001 |
OVAd-E2F1-E1A-△24-E1B-△19K-CMV-EGFP-Ad3FiberKnob |
Ad5 |
EGFP |
|
OVAD-002 |
OVAd-CMV-EGFP-E1A-E1B-19K |
Ad5 |
EGFP |
|
OVAD-003 |
OVAd-E1A-△24-E1B-EGFP-Ad5FiberRGD4C |
Ad5 |
EGFP |
|
OVAD-004 |
OVAd-E1A-△24-E1B-EGFP |
Ad5 |
EGFP |
|
OVAD-005 |
OVAd-E2F1-E1A-E1B-E3pro-GM-CSF-EGFP |
Ad5 |
EGFP |
|
OVAD-006 |
OVAd-E2F1-E1A-△24-E1B-△19K-E3pro-GM-CSF-mCherry-Ad3FiberKnob |
Ad5 |
mCherry |
|
OVAD-007 |
OVAd-E1A-△24-E1B-△19K-E3pro-GM-CSF-mCherry-Ad3FiberKnob |
Ad5 |
mCherry |
|
OVAD-008 |
OVAd-hTERT-E1A-IRES-E1B-EGFP |
Ad5 |
EGFP |
Vaccinia Virus (VACV)
Vaccinia virus replicates in the cytoplasm (eliminating risk of host genome integration), features a large genome with high cargo capacity (25–40 kb), and is well-suited for developing potently armed oncolytic vectors.
BrainVTA offers the Western Reserve (WR) strain with multiple engineering options. Our available stock products are listed below.
|
Catalog No. |
Product |
Strain |
Reporter |
Description |
|
VV01002 |
VV-△TK+EGFP |
Western Reserve |
EGFP |
Safety modifications: TK, I4L, A56R deletion |
|
VV03001 |
VV-△A56R-△TK |
Western Reserve |
— |
Safety modifications: TK, I4L, A56R deletion |
|
VV03002 |
VV-△TK+EGFP-△I4L |
Western Reserve |
EGFP |
Safety modifications: TK, I4L, A56R deletion |
Vesicular Stomatitis Virus (VSV)
VSV offers rapid replication, broad host tropism, and intrinsic tumor selectivity, making it a powerful oncolytic tool with fast killing kinetics.
BrainVTA provides VSV engineering services using the Indiana strain. Our available stock products are listed below.
|
Catalog No. |
Product |
Strain |
Reporter |
Description |
|
V01001 |
VSV-EGFP |
Indiana |
EGFP |
Safety/Targeting: LCMV-GP |
|
V01002 |
VSV-mCherry |
Indiana |
mCherry |
Safety/Targeting: LCMV-GP |
|
V01003 |
VSV Wild Type |
Indiana |
— |
Safety/Targeting: LCMV-GP |
|
V01004 |
VSV-LCMV-GP |
Indiana |
GFP |
Safety/Targeting: LCMV-GP |
Reovirus (ReV)
Reovirus exhibits natural tumor selectivity—preferentially replicating in cancer cells with activated Ras signaling—and features a double-stranded RNA genome. While its segmented genome limits cargo capacity (<2 kb), it offers excellent genetic stability and an inherent safety advantage.
BrainVTA offers the TD3 strain for oncolytic research.
|
Catalog No. |
Product |
Strain |
Reporter |
Description |
|
Reo1002 |
Reovirus Wild Type |
TD3 |
— |
— |
Preclinical Pharmacology Services
Our in vitro and in vivo pharmacology platform supports comprehensive evaluation of oncolytic virus efficacy, safety, and mechanism of action.
In Vitro Services
We maintain a broad panel of tumor cell lines—including HeLa, HCT116, HuH-7, HepG2, A549, A431, TE671, and K562—and offer customized cell line development to meet specific research needs. Services include:
-
Cell killing assays
-
Transgene expression analysis
-
Biomarker evaluation
In Vivo Services
Our established animal model platform includes:
-
Syngeneic tumor models
-
Xenograft models
-
Spontaneous tumor models
These enable rigorous evaluation of oncolytic virus efficacy, safety, and mechanism of action. Our experienced team works closely with clients to design and execute customized studies that accelerate preclinical development.
Contact Us
For more information about our oncolytic virus products and services, please contact us at
[email protected].
Return to top